VERTEX PHARMACEUTICALS INC / MA (VRTX)

Vertex Pharmaceuticals is a global biotechnology company focused on discovering and developing transformative medicines for people with serious diseases, concentrating on specialty markets. The company markets seven approved medicines: five CFTR modulator therapies for cystic fibrosis (ALYFTREK, TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO), CASGEVY, an ex-vivo CRISPR/Cas9 gene-edited cell therapy developed with collaborator CRISPR Therapeutics for severe sickle cell disease and transfusion-dependent beta thalassemia, and JOURNAVX (suzetrigine), a non-opioid NaV1.8 pain signal inhibitor approved for moderate-to-severe acute pain. Its CF medicines collectively treat nearly three-quarters of the roughly 94,000 people with CF across the U.S., Europe, Australia, and Canada, while CASGEVY addresses an estimated 60,000 eligible people with severe SCD or TDT, and JOURNAVX targets a U.S. acute pain population exceeding 80 million annual prescriptions.

Beyond these approved products, the company maintains an extensive clinical-stage pipeline spanning CF (including the mRNA therapeutic VX-522, developed with Moderna), SCD/TDT expansion into younger patients and next-generation conditioning agents, acute and peripheral neuropathic pain (VX-993 and suzetrigine in diabetic peripheral neuropathy and lumbosacral radiculopathy), APOL1-mediated kidney disease (inaxaplin), IgA nephropathy and other autoimmune renal diseases (povetacicept, gained through its Alpine Immune Sciences acquisition), type 1 diabetes (zimislecel and VX-264, stemming from its Semma Therapeutics acquisition), myotonic dystrophy type 1 (VX-670, licensed from Entrada Therapeutics), and autosomal dominant polycystic kidney disease (VX-407). The company's research strategy emphasizes validated causal human biology, predictive biomarkers, and multiple modalities—including small molecules, mRNA therapeutics, gene-editing, and cell therapies—pursued through internal discovery, business development, and collaborations with biopharmaceutical and academic partners. Its markets span more than 60 countries, supported by a growing network of authorized treatment centers for CASGEVY and expanding reimbursement and access initiatives for its CF and pain therapies, with continued investment in manufacturing infrastructure, including a Boston-based cell and gene therapy campus, to support its serial innovation approach and long-term pipeline growth across specialty disease areas.